WIN 54954_product_DataBase

Bioactivity	WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections[1][2].
Invitro	WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL)[1].WIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/mL[1].
In Vivo	WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus A-9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively[1].
Name	WIN 54954
CAS	107355-45-3
Formula	C18H20Cl2N2O3
Molar Mass	383.27
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Woods MG, et, al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. [2]. Fechner H, et, al. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503.

PeptideDB